Screener
CytomX Therapeutics CTMX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue, current portion | 24,073 | 26,877 |
| Total current liabilities | 39,861 | 46,615 |
| Deferred revenue, net of current portion | 30,617 | 1,590 |
| Operating lease liabilities - long term | 4,208 | — |
| Other long-term liabilities | 4,472 | 4,353 |
| Total liabilities | 79,158 | 52,558 |
| Commitments and contingencies | ||
| Stockholders' equity: |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's operating lease liabilities?
- CytomX Therapeutics (CTMX) reported operating lease liabilities of $4.21M in Q2 2026.
- How has CytomX Therapeutics's operating lease liabilities changed year-over-year?
- CytomX Therapeutics's operating lease liabilities increased by 191.8% year-over-year, from $1.44M to $4.21M.
- What is the long-term trend for CytomX Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), CytomX Therapeutics's operating lease liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $21.68M to $0.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about CytomX Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude